FDA grants Fast Track designation for Farxiga in chronic kidney disease
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the progression of renal failure and prevent cardiovascular (CV) and renal death in patients with chronic kidney disease (CKD).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
More News: AstraZeneca | Cardiology | Cardiovascular | Chronic Kidney Disease | Dapagliflozin | Food and Drug Administration (FDA) | Forxiga | Grants | Heart | Pharmaceuticals | Renal Failure | Urology & Nephrology